7th Genome Editing Therapeutics Summit

Memo

The FDA has shown its' hand. The Plausible Mechanism Framework and new NGS safety guidance signal one thing clearly: regulators want genome editing therapies to reach patients. Biopharma are also pushing back with a surge of novel genome editing assets deployed in the last 2 years, targeting rare and prevalent diseases with scarce treatment options. But intent and support alone won't get these therapies to patients. Developmental, manufacturing, and regulatory challenges still stand between the lab and the patients waiting. That's why the 7th Genome Editing Therapeutics Summit returns to Boston in 2026 where R and D, preclinical, translational, regulatory, and c-suite leaders will come together to answer one question: how do we maximize the application of genome editing therapies to patients who need them most? Don't miss out on insights from AbbVie, Bristol Myers Squibb, Intellia Therapeutics, Beam Therapeutics, Sanofi, and others on how genome editing can move from a promising therapy to an essential one for patients facing the most genetically complex diseases. URLs:Tickets: https://go.evvnt.com/3647164-2?pid=5569Brochure: https://go.evvnt.com/3647164-3?pid=5569 Date and Time: Tuesday, 29 September 2026 at 08:00 - Wednesday, 30 September 2026 at 17:00 Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals Prices:Conference Only - Drug Developer, Academic or Research Institutes Pricing: USD 0.00,Conference Only - Solution Provider Pricing: USD 3899.00 Speakers: Devyn Smith, Chief Executive Officer, Arbor Biotechnologies, Kyle Watters, Director, Precision Editing, Arbor Biotechnologies, Lalit Kumar, Director, Clinical Bioanalytics and Translational Sciences, Beam Therapeutics, Gopi Shanker, Chief Scientific Officer, Beam Therapeutics, Lauren Young, Senior Director, Genomics and Computational Biology, Beam Therapeutics, Bin Wu, Founder and Chief Executive Officer, Cytodigm, Kelan Hlavaty, Senior Director and Head, Analytical Development and Quality Control, eGenesis Bio, Wenning Qin, Senior Vice President, Research, eGenesis Bio, Noa Wertheimer, Director, Scientific Strategy, Emendo Biotherapeutics, Xiao Yang, Senior Principal Scientist, Epicripsr Biotechnologies, Howard Wu, Co-Founder and Chief Scientific Officer, Full Circle Therapeutics, Brad Ringeisen, Executive Director, Innovative Genomics Initiative, Birgit Schultes, Chief Scientific Officer, Intellia Therapeutics, Jesse Owens, Chief Scientific Advisor, Komo Biosciences, Alan Brooks, Vice President, Preclinical Research, Metagenomi Therapeutics, Cindy Liu, Director, Molecular Analytical Development, Prime Medicine, Ishani Dasgupta, Senior Scientist, AbbVie, Matthew Laurie, Senior Scientist, Bristol Myers Squibb, John Moore, Senior Director, Translational Gene Editing, Eli Lilly, Wei-Chiang, Chen Associate Director, Sanofi